A chemokine receptor as a novel treatment target of age-related macular degeneration,

Research Project

Project/Area Number	23592552
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Ophthalmology
Research Institution	The University of Tokyo
Principal Investigator	YANAGI Yasuo 東京大学, 医学部附属病院, 講師 (90376442)
Project Period (FY)	2011 – 2013
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000) Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Keywords	加齢黄斑変性 / ケモカイン / CXCR3 / 脈絡膜新生血管
Research Abstract	This study investigated the effects of inflammatory cytokine, IP-10, on choroidal neovascularization due to age-related macular degeneration. The results demonstrated that IP-10 is produced in the inflammatory macrophage and retinal pigment epithelial cells and inhibits choroidal neovascularization through its receptor, CXCR3. This study identified a new treatment target for age-related macular degeneration, a devastating condition leading to legal blindness.